Tata Medical and Diagnostics, a healthcare venture from the Tata group, announced the commercial launch of TataMD CHECK, a diagnostic gene-based testing kit for Covid-19. TataMD CHECK is powered by’Feluda’, a CRISPR Cas-9 technology developed indigenously by leading research institute, CSIR- IGIB, making it the first such diagnostic tool to be launched globally.
The company claims a quicker, simpler and cheaper process through the use of these kits, as against the other technology, RT-PCR (Reverse transcription polymerase chain reaction) -- considered the gold standard method for Covid-19 testing. The process of collecting patient samples, RNA extraction and amplification etc remains the same, but uses simple, less expensive equipment and produces quicker results due to a more agile process and AI-based automated result detection, says a company statement.
Details about the price of the kit were not available.
The test kits will be manufactured at a facility near Chennai, which has a capacity of producing one million kits in a month. The company is also tying up with diagnostic chains, hospitals, healthcare centres, apart from partnering with government agencies.